Bcl11a Activators
Bcl11a activators are a class of chemicals that interact with the Bcl11a protein to enhance its activity. The discovery and analysis of such activators typically begin with the process of high-throughput screening (HTS). HTS is a method where a large library of diverse chemical compounds is systematically tested to identify those that can increase the functional activity of Bcl11a. This screening involves the use of assays that are finely tuned to detect changes in Bcl11a activity, often leveraging technologies that produce detectable signals, such as fluorescence or luminescence, in response to protein activation. Compounds that yield a positive change in signal, which indicates elevated activity of Bcl11a, are selected for further scrutiny. Following HTS, the compounds that show promise undergo a series of secondary assays. These assays are designed to confirm the results of the HTS by providing a more refined analysis of the compound's ability to specifically activate Bcl11a. They help to exclude false positives that may arise from nonspecific interactions or compounds that indirectly affect the assay readout rather than directly influencing Bcl11a activity.
Once a group of compounds has been confirmed as potential Bcl11a activators through secondary assays, they move on to a detailed characterization phase. This phase involves using techniques such as X-ray crystallography or cryo-electron microscopy to obtain high-resolution structures of the Bcl11a protein in complex with the activators. By doing so, researchers can visualize the exact manner in which these molecules engage with Bcl11a and pinpoint the molecular interactions that lead to the increase in its activity. Alongside structural studies, biophysical methods such as surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) are employed to quantitatively assay the binding kinetics and affinity of the activators to Bcl11a.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $56.00 $156.00 $270.00 $665.00 | 37 | |
Prostaglandin E2 interacts with its G protein-coupled receptor EP4, leading to increased intracellular cAMP and PKA activity. This signaling can enhance Bcl11a function by modulating proteins that associate with or regulate Bcl11a activity. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels, which can activate calcium-dependent protein kinases. These kinases could influence Bcl11a activity by modifying the phosphorylation state of proteins that regulate Bcl11a. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA is a PKC activator. PKC-mediated signaling pathways might influence Bcl11a by altering the phosphorylation status of proteins that interact with or regulate Bcl11a, potentially enhancing its functional activity. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX is a nonspecific inhibitor of phosphodiesterases, leading to increased cAMP levels and PKA activity. PKA may affect Bcl11a activity by phosphorylating regulatory proteins or altering Bcl11a's protein interactions. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
A23187 is a calcium ionophore that increases intracellular calcium concentration, potentially activating calcium-dependent kinases that could modulate Bcl11a activity through phosphorylation of proteins within Bcl11a's regulatory network. | ||||||
(±)-Bay K 8644 | 71145-03-4 | sc-203324 sc-203324A sc-203324B | 1 mg 5 mg 50 mg | $82.00 $192.00 $801.00 | ||
Bay K8644 is an L-type calcium channel agonist, which increases intracellular calcium levels and can activate calcium-dependent signaling pathways, potentially enhancing Bcl11a activity through the phosphorylation of associated regulatory proteins. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
Rolipram is a selective inhibitor of phosphodiesterase 4, elevating intracellular cAMP levels and activating PKA. This activation may enhance Bcl11a activity by phosphorylation of proteins within the Bcl11a signaling network. | ||||||
Chelerythrine chloride | 3895-92-9 | sc-3547 sc-3547A | 5 mg 25 mg | $88.00 $311.00 | 17 | |
Chelerythrine is a PKC inhibitor, which can shift the balance of cellular signaling, potentially enhancing Bcl11a activity indirectly by modulating the phosphorylation state of proteins that either regulate or interact with Bcl11a. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $45.00 $130.00 $480.00 $4450.00 | 74 | |
Dibutyryl cAMP is a cAMP analog that activates PKA. PKA may enhance Bcl11a activity by altering the phosphorylation status of proteins within the Bcl11a regulatory framework, potentially influencing Bcl11a's functional role. | ||||||
Vinpocetine | 42971-09-5 | sc-201204 sc-201204A sc-201204B | 20 mg 100 mg 15 g | $55.00 $214.00 $2400.00 | 4 | |
Vinpocetine is a phosphodiesterase 1 inhibitor, which increases cAMP and cGMP levels, leading to the activation of PKA and PKG, respectively. These kinases could enhance Bcl11a activity by modulating the phosphorylation of Bcl11a or its associated proteins. | ||||||